To the full analysis
Abbott Laboratories stock: growth
ABTAbbott Laboratories reported $44.33B in revenue for fiscal 2025, up 5.7% on the prior year, up 5.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
3.6%
per year from 2006 to 2025, per share 2.9%
Earnings (Annual rate)
7.3%
per year from 2006 to 2025, per share 6.6%
Free cash flow (Annual rate)
3.3%
per year from 2006 to 2025, per share 2.6%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 5.1% | 8.1% | 3.6% |
| Revenue per share | 5.4% | 6.2% | 2.9% |
| Earnings | 7.7% | 4.0% | 7.3% |
| Earnings per share | 8.2% | 2.2% | 6.6% |
| Free cash flow | 5.3% | 14.8% | 3.3% |
| Free cash flow per share | 5.6% | 12.9% | 2.6% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $22.48B | $1.72B | $3.99B |
| 2007 | $25.91B | $3.61B | $3.53B |
| 2008 | $29.53B | $4.88B | $6.06B |
| 2009 | $30.77B | $5.75B | $6.19B |
| 2010 | $35.17B | $4.63B | $7.72B |
| 2011 | $38.85B | $4.73B | $7.48B |
| 2012 | $39.87B | $5.96B | $7.52B |
| 2013 | $21.85B | $2.58B | $2.18B |
| 2014 | $20.25B | $2.28B | $2.6B |
| 2015 | $20.41B | $4.42B | $1.86B |
| 2016 | $20.85B | $1.4B | $2.08B |
| 2017 | $27.39B | $477M | $4.44B |
| 2018 | $30.58B | $2.37B | $4.91B |
| 2019 | $31.9B | $3.69B | $4.5B |
| 2020 | $34.61B | $4.5B | $5.72B |
| 2021 | $43.08B | $7.07B | $8.65B |
| 2022 | $43.65B | $6.93B | $7.8B |
| 2023 | $40.11B | $5.72B | $5.06B |
| 2024 | $41.95B | $13.4B | $6.35B |
| 2025 | $44.33B | $6.52B | $7.4B |
Revenue by segment
How Abbott Laboratories makes its money and how that has shifted. Names are as the company reports them.
- Medical Devices48%
- Diagnostic Products20%
- Nutritional Products19%
- Established Pharmaceutical Products12%
- Other< 1%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Medical Devices | $8.91B | $9.44B | $12.24B | $11.79B | $14.37B | $14.69B | $16.89B | $18.99B | $21.39B | 48.2% |
| Diagnostic Products | $5.62B | $7.5B | $7.71B | $10.81B | $15.64B | $16.58B | $9.99B | $9.34B | $8.94B | 20.2% |
| Nutritional Products | $6.93B | $7.23B | $7.41B | $7.65B | $8.29B | $7.46B | $8.15B | $8.41B | $8.45B | 19.1% |
| Established Pharmaceutical Products | $4.29B | $4.42B | $4.49B | $4.3B | $4.72B | $4.91B | $5.07B | $5.19B | $5.54B | 12.5% |
| Other | $1.65B | $2B | $0 | $0 | $0 | $0 | $0 | $0 | $0 | 0% |
| Total revenue | $27.39B | $30.58B | $31.9B | $34.61B | $43.08B | $43.65B | $40.11B | $41.95B | $44.33B | 100% |
Revenue by region
Where Abbott Laboratories generates its revenue.
- United States39%
- Outside the US36%
- D [E]6%
- C [N]4%
- I [N]4%
- C [H]4%
- Other6%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| United States | $10.84B | $11.4B | $13.02B | $16.64B | $18.14B | $15.45B | $16.32B | $17.13B | 38.6% |
| Outside the US | $11.22B | $11.53B | $12.58B | $15.52B | $14.84B | $14.08B | $14.85B | $15.98B | 36% |
| D [E] | $1.62B | $1.75B | $2.11B | $2.57B | $2.34B | $2.35B | $2.54B | $2.76B | 6.2% |
| C [N] | $2.31B | $2.35B | $1.97B | $2.39B | $2.13B | $2.25B | $2.11B | $1.91B | 4.3% |
| I [N] | $1.33B | $1.4B | $1.32B | $1.56B | $1.65B | $1.75B | $1.82B | $1.87B | 4.2% |
| C [H] | $1.01B | $1.07B | $1.14B | $1.31B | $1.34B | $1.64B | $1.75B | $1.87B | 4.2% |
| Other | $2.26B | $2.41B | $2.47B | $3.08B | $3.21B | $2.59B | $2.57B | $2.82B | 6.4% |
| Total revenue | $30.58B | $31.9B | $34.61B | $43.08B | $43.65B | $40.11B | $41.95B | $44.33B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 23 Jan 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.